Kathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More